Skip to main content

Table 6 Clinical studies of valproic acid

From: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

Phase

Other agent

Disease (pt. No.)

Schedule

Recommended dose & response

Reference

I

ATRA(80 mg/m2)

AML (58).

Twice a day

VPA serum concentration to 50-100 ug/ml

[131]

I

 

Cervical cancer(12)

Once a day

20-40 mg/kg

[137]

I

ATRA(45 mg/m2)

AML(26)

Once a day

5-10 mg/kg

[132]

I

Decitabine (5 mg/m2)

NSCLC(8)

5-aza-CdR for 10 days in combination with VA on days 5-21 of a 28-day cycle.

15 mg/kg/d

[140]

I

 

Refractory advanced cancer(26)

Daily for 5 days in a 21-day cycle

60 mg/kg/day

[138]

I

Epirubicin

Solid tumor(44)

Daily for three days then followed by epirubicin in 21 day cycle

VPA 140 mg/kg/d

Epirubincin 100 mg/m2

[139]

I

AZA and ATRA

AML(49) and MDS(4)

 

VPA 75 mg/kg

[136]

I and II

Decitabine(15 mg/m2)

AML(54)

Once a day

50 mg/kg, 22% objective response

[134]